GlassScriptPhysician profile
Elena Dragun
NPI 1467413583
$4,736.53
in general payments reported to CMS, 2019-2025
29 companies · $860 in 2025
The $860 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $544 · 2021: $875 · 2022: $529 · 2023: $434 · 2024: $559 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $946.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.03 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $590.59 | 2019-2025 | Zoryve, Livalo |
| Abbvie INC. | $457.73 | 2019-2025 | Viberzi, Linzess, Vraylar |
| Novo Nordisk INC | $348.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $327.92 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $137.64 | 2019-2022 | |
| Abbott Laboratories | $137.09 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $124.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.73 | 2025 | Breyanzi |
| Genentech USA, INC. | $121.03 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $116.34 | 2019-2022 | |
| Amgen INC. | $114.65 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $70.59 | 2019-2021 | |
| Pfizer INC. | $65.70 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.53 | 2022-2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $55.64 | 2021 | |
| Allergan, INC. | $43.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.24 | 2023-2025 | |
| Exact Sciences Corporation | $33.04 | 2025 | The Cologuard Plus Collection Kit |
| Azurity Pharmaceuticals, INC. | $30.75 | 2023 | Edarbi, Adthyza |
| Horizon Therapeutics Plc | $25.28 | 2020-2021 | |
| Dexcom, INC. | $18.30 | 2025 | Dexcom G6 Transmitter |
| Alk-Abello, INC | $15.64 | 2025 | Neffy |
| Vivus LLC | $14.67 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.40 | 2019 | |
| Sanofi Pasteur INC. | $13.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.09 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Dragun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.